Clinical trials: Patients with Advanced Solid Tumors
Solid Tumor, Adult
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
- Trial name
- NCT06265727
- Testing
- CRB-701, Anti-PD-1
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 348 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Non-Small-Cell Lung Carcinoma, Prostate Cancer
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Vorinostat (Suberoylanilide Hydroxamic Acid; NSC 701852) is a drug that inhibits an enzyme that plays a key role in the regulation of cell survival, growth, and eventual cell death, all of which play a role in cancer.
- Conditions
- Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT00565227
- Testing
- vorinostat (suberoylanilide hydroxamic acid), docetaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Advanced Tumors
Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors
The main purpose of this study was to evaluate the safety and tolerability of CDP1 in patients with advanced solid tumor, to explore dose limited toxicity (DLT), and to determine the recommended dose (RP2D) for phase II clinical…
- Trial name
- NCT04151810
- Testing
- CDP1, TIP chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Advanced Solid Malignancies
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced…
- Trial name
- NCT03394144
- Testing
- AZD9150, Durvalumab
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Tumors
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced…
- Trial name
- NCT00395434
- Testing
- Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Mateon Therapeutics
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Neoplasms
First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors
Analysis of safety, tolerability, and PK data will provide information that will guide future development of AB0024.
- Trial name
- NCT01323933
- Testing
- AB0024
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine the maximum tolerable dose (MTD) and/or recommended phase 2 dose (RP2D) of HH30134 administered orally on a continuous…
- Trial name
- NCT04746612
- Testing
- HH30134
- Where
- 4 sites in Australia, China
- Volunteers
- 22 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of YL202 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT07202364
- Testing
- YL202
- Where
- China
- Volunteers
- 100 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Mesothelin-Positive Advanced Solid Tumors With Peritoneal Metastasis
A Study of Mesothelin-Targeted CAR-Mix Cells in Patients With Advanced Solid Tumors
An exploratory, open-label, single-arm, dose-escalation clinical study evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary antitumor activity of intraperitoneally administered SY001…
- Trial name
- NCT07909434
- Testing
- SY001
- Volunteers
- 10 people
- Sponsor
- Zhejiang University
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors
The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors.
- Trial name
- NCT04843033
- Testing
- SH3809 tablet
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the…
- Trial name
- NCT07407933
- Testing
- YL201, Atezolizumab
- Where
- 38 sites in United States, Belgium and 7 more
- Volunteers
- 118 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Neoplasm, Malignant
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
This study will assess if the combination of sunitinib and pemetrexed is tolerable when coadministered at each recommended dose/schedule.
- Trial name
- NCT00732992
- Testing
- Sunitinib, Pemetrexed
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- Pfizer
Advanced Solid Tumor
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Primary objectives: To evaluate the safety and tolerability of BAT1006 in patients with advanced her2-positive solid tumors. To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
- Trial name
- NCT05414136
- Testing
- BAT1006
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Bio-Thera Solutions
Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations.
- Trial name
- BOREALIS-1 (NCT07021898)
- Testing
- ERAS-4001, ERAS-4001 in combination
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Erasca, Inc.
Advanced Solid Tumors
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
- Trial name
- NCT07601334
- Testing
- HF50
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- HighField Biopharmaceuticals Corporation
Solid Cancers
A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of MNRP1685A administered by IV infusion every 3 weeks in patients with locally advanced or metastatic solid tumors for whom standard therapy either does not…
- Trial name
- NCT00747734
- Testing
- MNRP1685A
- Volunteers
- 35 people
- Sponsor
- Genentech, Inc.
Tumors
An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours
Maximum Tolerated Dose (MTD), safety, pharmacokinetics, efficacy of BIBF 1120, pharmacodynamic parameters (Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI))
- Trial name
- NCT02182206
- Testing
- BIBF 1120
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Neoplasm Metastases
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of ketoconazole on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01267084
- Testing
- Trabectedin, Ketoconazole, Dexamethasone or equivalent steroid
- Where
- 2 sites in Belgium
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.